Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Cooper, Zachary A ^a   Reuben, Alexandre ^a   Spencer, Christine N ^a   Prieto, Peter A ^a   Austin Breneman, Jacob L ^a   Jiang, Hong ^a   Haymaker, Cara ^a   Gopalakrishnan, Vancheswaran ^a   Tetzlaff, Michael T ^a   Frederick, Dennie T ^b   Sullivan, Ryan J ^b   Amaria, Rodabe N ^a   Patel, Sapna P ^a   Hwu, Patrick ^a   Woodman, Scott E ^a   Glitza, Isabella C ^a   Diab, Adi ^a   Vence, Luis M ^a   Rodriguez Canales, Jaime ^a   Parra, Edwin R ^a   Wistuba, Ignacio I ^a   Coussens, Lisa M ^c   Sharpe, Arlene H ^d   Flaherty, Keith T ^b   Gershenwald, Jeffrey E ^a   Chin, Lynda ^a   Davies, Michael A ^a   Clise Dwyer, Karen ^a   Allison, James P ^a   Sharma, Padmanee ^a   Wargo, Jennifer A ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BRAF; CTLA 4; Immune checkpoint blockade; melanoma; PD 1; targeted therapy

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANZYME B; INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; PEMBROLIZUMAB; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; TRAMETINIB; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; PROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

EID: 84961621847     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1136044     Document Type: Article

References (30)

1. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
2. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
3. K.T.Flaherty, J.R.Infante, A.Daud, R.Gonzalez, R.F.Kefford, J.Sosman, O.Hamid, L.Schuchter, J.Cebon, N.Ibrahim et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Eng J Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093
4. J.A.Sosman, K.B.Kim, L.Schuchter, R.Gonzalez, A.C.Pavlick, J.S.Weber, G.A.McArthur, T.E.Hutson, S.J.Moschos, K.T.Flaherty et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Eng J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
5. P.B.Chapman, A.Hauschild, C.Robert, J.B.Haanen, P.Ascierto, J.Larkin, R.Dummer, C.Garbe, A.Testori, M.Maio et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
6. C.Robert, J.Schachter, G.V.Long, A.Arance, J.J.Grob, L.Mortier, A.Daud, M.S.Carlino, C.McNeil, M.Lotem et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Eng J Med 2015; 372(26):2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
7. J.A.Wargo, Z.A.Cooper, K.T.Flaherty Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov 2014; 4:1377-86; PMID:25395294; http://dx.doi.org/10.1158/2159-8290.CD-14-0477
8. C.Robert, B.Karaszewska, J.Schachter, P.Rutkowski, A.Mackiewicz, D.Stroiakovski, M.Lichinitser, R.Dummer, F.Grange,L.Mortier et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Eng J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
9. G.V.Long, D.Stroyakovskiy, H.Gogas, E.Levchenko, F.de Braud, J.Larkin, C.Garbe, T.Jouary, A.Hauschild, J.J.Grob et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386(9992):444-51; PMID:26037941; http://dx.doi.org/10.1016/S0140-6736(15)60898-4
10. A.Hauschild, J.J.Grob, L.V.Demidov, T.Jouary, R.Gutzmer, M.Millward, P.Rutkowski, C.U.Blank, W.H.Miller, Jr, E.Kaempgen et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
11. D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33(17):1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
12. A.Ackerman, O.Klein, D.F.McDermott, W.Wang, N.Ibrahim, D.P.Lawrence, A.Gunturi, K.T.Flaherty, F.S.Hodi, R.Kefford et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120:1695-701; PMID:24577748; http://dx.doi.org/10.1002/cncr.28620
13. P.A.Ascierto, E.Simeone, V.C.Sileni, M.Del Vecchio, P.Marchetti, G.C.Cappellini, R.Ridolfi, F.de Rosa, F.Cognetti, V.Ferraresi et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014; 32:144-9; PMID:24484235; http://dx.doi.org/10.3109/07357907.2014.885984
14. P.A.Ascierto, K.Margolin Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. Cancer 2014; 120:1617-9; PMID:24577788; http://dx.doi.org/10.1002/cncr.28622
15. M.S.Schreuer, I.L.Chevolet, Y.J.Jansen, T.C.Seremet, S.Wilgenhof, D.Lienard, V.Del Marmol, B.Neyns Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res 2015; 25:68-74; PMID:25396684; http://dx.doi.org/10.1097/CMR.0000000000000131
16. J.Larkin, C.D.Lao, W.J.Urba, D.F.McDermott, C.Horak, J.Jiang, J.D.Wolchok Efficacy and Safety of Nivolumab in PatientsWith BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. JAMA Oncol 2015; 1:433-40; PMID:26181250; http://dx.doi.org/10.1001/jamaoncol.2015.1184
17. Z.A.Cooper, V.R.Juneja, P.T.Sage, D.T.Frederick, A.Piris, D.Mitra, J.A.Lo, F.S.Hodi, G.J.Freeman, M.W.Bosenberg et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014; 2:643-54; PMID:24903021; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215
18. P.C.Tumeh, C.L.Harview, J.H.Yearley, I.P.Shintaku, E.J.Taylor, L.Robert, B.Chmielowski, M.Spasic, G.Henry, V.Ciobanu et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954
19. A.A.Tarhini, H.Edington, L.H.Butterfield, Y.Lin, Y.Shuai, H.Tawbi, C.Sander, Y.Yin, M.Holtzman, J.Johnson et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PloS One 2014; 9:e87705; PMID:24498358; http://dx.doi.org/10.1371/journal.pone.0087705
20. D.T.Frederick, A.Piris, A.P.Cogdill, Z.A.Cooper, C.Lezcano, C.R.Ferrone, D.Mitra, A.Boni, L.P.Newton, C.Liu et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
21. Z.A.Cooper, D.T.Frederick, V.R.Juneja, R.J.Sullivan, D.P.Lawrence, A.Piris, A.H.Sharpe, D.E.Fisher, K.T.Flaherty, J.A.Wargo BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunol 2013; 2:e26615; PMID:24251082; http://dx.doi.org/10.4161/onci.26615
22. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Eng J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
23. B.Ruffell, A.Au, H.S.Rugo, L.J.Esserman, E.S.Hwang, L.M.Coussens Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012; 109:2796-801; PMID:21825174; http://dx.doi.org/10.1073/pnas.1104303108
24. J.S.Wilmott, G.V.Long, J.R.Howle, L.E.Haydu, R.N.Sharma, J.F.Thompson, R.F.Kefford, P.Hersey, R.A.Scolyer Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479
25. H.Kakavand, J.S.Wilmott, A.M.Menzies, R.Vilain, L.E.Haydu, J.H.Yearley, J.F.Thompson, R.F.Kefford, P.Hersey, G.V.Long et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clin Cancer Res 2015; 21(14):3140-8; PMID:25609064; http://dx.doi.org/10.1158/1078-0432.CCR-14-2023
26. Z.A.Cooper, A.Reuben, R.N.Amaria, J.A.Wargo Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunol 2014; 3:e954956; PMID:25941608; http://dx.doi.org/10.4161/21624011.2014.954956
27. S.R.Woo, M.E.Turnis, M.V.Goldberg, J.Bankoti, M.Selby, C.J.Nirschl, M.L.Bettini, D.M.Gravano, P.Vogel, C.L.Liu et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
28. M.Atkins Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. Semin Oncol 2015; 42 Suppl 3:S12-9; PMID:26598055; http://dx.doi.org/10.1053/j.seminoncol.2015.10.002
29. J.M.Chauvin, O.Pagliano, J.Fourcade, Z.Sun, H.Wang, C.Sander, J.M.Kirkwood, T.H.Chen, M.Maurer, A.J.Korman et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 2015; 125:2046-58; PMID:25866972; http://dx.doi.org/10.1172/JCI80445
30. L.Chin, J.A.Wargo, D.J.Spring, H.Kantarjian, P.A.Futreal Cancer Genomics in clinical context. Trends Cancer 2015; 1:36-43; http://dx.doi.org/10.1016/j.trecan.2015.07.010